Eloxatin
Donafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Donafenib cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Donafenib Sun Yat-sen University | Phase 2 | B |
Theprubicin Shanghai Zhongshan Hospital | Phase 2 | B |
Ethiodized Oil Shanghai Zhongshan Hospital | Phase 2 | B |
FLUOROURACILUM Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | B |
Calcium folinate pentahydrate Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | B |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →